NBY Form 3: Lazar Purchases Convertible Preferred Equivalent to 77M Common
Rhea-AI Filing Summary
NovaBay Pharmaceuticals reported that David E. Lazar, the company's Chief Executive Officer and a director, agreed to purchase convertible preferred stock that converts into a substantial number of common shares. Under the securities purchase agreement, Mr. Lazar acquired 481,250 shares of Series D Convertible Preferred Stock at $20.00 per share for $3,850,000 and agreed to purchase 268,750 shares of Series E Convertible Preferred Stock at $20.00 per share in a subsequent closing for $2,150,000. Each Series D and Series E share converts into 160 shares of common stock, and the Series D closing resulted in conversion rights to 77,000,000 common shares. The Series D is perpetual and convertible at the holder’s option, while the Series E purchase is subject to closing conditions.
Positive
- Insider alignment: The CEO and director made a significant personal investment, buying Series D preferred for $3,850,000 and committing to Series E for $2,150,000.
- Convertible structure provides flexibility: The preferred shares convert into common stock at the holders option, offering liquidity and strategic flexibility to the reporting person.
Negative
- Potential material dilution: Series D converts into 77,000,000 common shares, which is a large issuance relative to typical public-company float.
- Pending financing conditional: The Series E purchase is subject to closing conditions, meaning the full committed stake is not yet finalized.
Insights
TL;DR: CEO's large preferred-stock purchase creates potential for significant equity dilution but signals substantial insider commitment.
The reporting shows the CEO and director executed a private purchase of convertible preferred securities totaling $3.85 million at initial close with a further $2.15 million commitment pending. The convertible terms—160 common shares per preferred share—mean the Series D acquired converts into 77,000,000 common shares if converted, an amount that is clearly material to the companys equity base. This transaction is economically significant for both ownership structure and potential future dilution if conversion occurs. The pending Series E closing adds conditional upside to the insider stake.
TL;DR: Insider purchase by CEO/director raises alignment with shareholders but requires scrutiny of voting, ownership limits, and conversion controls.
The form identifies Mr. Lazar as Director, Chief Executive Officer, and a 10% owner, indicating a prominent insider role. The acquisition via preferred shares that are perpetual and convertible at the holders option can shift control or influence depending on conversion and any ownership limitations referenced. The outstanding conversion capacity and the conditional Series E closing merit attention to governance provisions, anti-dilution mechanisms, and any restrictions on conversion to ensure minority shareholder protections remain intact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series D Convertible Preferred Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- No shares of Common Stock are beneficially owned. On August 19, 2025, David E. Lazar (the "Reporting Person") and NovaBay Pharmaceuticals, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire (i) an aggregate of 481,250 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock") at a price of $20.00 per share and (ii) an aggregate of 268,750 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a price of $20.00 per share. Each share of Series D Preferred Stock is convertible into 160 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on August 19, 2025, whereby the Reporting Person acquired 481,250 shares of Series D Preferred Stock for a total purchase price of $3,850,000. The Reporting Person will acquire the shares of Series E Preferred Stock at a subsequent closing, subject to satisfaction of certain closing conditions, for a total purchase price of $2,150,000. Each share of Series E Preferred Stock will be convertible into 160 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The Series D Preferred Stock is perpetual and therefore has no expiration date. The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
